Comprehensive genomic and immune profiling (CGIP) reveals a distinct genomic and immune gene expression profile for younger patients with non-small cell lung cancer (NSCLC)

Tumors of younger patients with NSCLC had distinct genomic profiles with more targetable alterations, but lower mutational burden and immunogenicity compared to older patient tumors. These findings suggest that younger patients with NSCLC may benefit more from targeted therapy than immunotherapy, emphasizing the importance of expanding insurance coverage for genomic profiling in younger patients with NSCLC.